Liver transplantation: Current indications and patient selection for adult patients with chronic liver disease

Journal of the Medical Association of Thailand

Volumn 91, Issue 10, 2008, Pages 1623-1632

  Apiratpracha, Wichian ^a,b   Chailimpamontree, Worawon ^c   Intraprasong, Phongphob ^b   Yoshida, Eric M ^b  

^a PRAMONGKUTKLAO HOSPITAL   (Thailand)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

Author keywords

Chronic liver disease; Current indications; Liver transplant; Patient selection; Timing

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; INTERFERON; LAMIVUDINE; RIBAVIRIN; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL LIVER DISEASE; BILE DUCT CARCINOMA; CHRONIC LIVER DISEASE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PATIENT SELECTION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SURVIVAL RATE; TREATMENT INDICATION;

ADULT; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; PATIENT SELECTION; TIME FACTORS;

EID: 55249126379     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-32.
2. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-26.
3. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-11.
4. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-7.
5. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-95.
6. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-6.
7. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-27.
8. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
9. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581-6.
10. Neff GW, O'brien CB, Nery J, Shire N, Montalbano M, Ruiz P, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-8.
11. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
12. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
13. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-10.
14. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.
15. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-8.
16. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-35.
17. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968-74.
18. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-5.
19. Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501.
20. Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176-81.
21. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9: S90-4.
22. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32(4 Pt 1): 852-8.
23. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92.
24. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30.
25. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120-30.
26. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-50.
27. Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283-7.
28. Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 1253-8.
29. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-74.
30. Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 3042-4.
31. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77: 190-4.
32. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20(4 Pt 1): 773-9.
33. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859-67.
34. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941-9.
35. Starzl TE, Van Thiel D, Tzakis AG, Iwatsuki S, Todo S, Marsh JW, et al. Orthotopic liver transplantation for alcoholic cirrhosis. JAMA 1988; 260: 2542-4.
36. Lim JK, Keeffe EB. Liver transplantation for alcoholic liver disease: current concepts and length of sobriety. Liver Transpl 2004; 10(10 Suppl 2): S31-S38.
37. Berlakovich GA, Soliman T, Freundorfer E, Windhager T, Bodingbauer M, Wamser P, et al. Pre-transplant screening of sobriety with carbohydrate- deficient transferrin in patients suffering from alcoholic cirrhosis. Transpl Int 2004; 17: 617-21.
38. McMaster P. Transplantation for alcoholic liver disease in an era of organ shortage. Lancet 2000; 355: 424-5.
39. Zibari GB, Edwin D, Wall L, Diehl A, Fair J, Burdick J, et al. Liver transplantation for alcoholic liver disease. Clin Transplant 1996; 10(6 Pt 2): 676-9.
40. Howard L, Fahy T, Wong P, Sherman D, Gane E, Williams R. Psychiatric outcome in alcoholic liver transplant patients. QJM 1994; 87: 731-6.
41. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-76.
42. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
43. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
44. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
45. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003; 238: 885-92.
46. Markus BH, Dickson ER, Grambsch PM, Fleming TR, Mazzaferro V, Klintmalm GB, et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320: 1709-13.
47. Kim WR, Wiesner RH, Therneau TM, Poterucha JJ, Porayko MK, Evans RW, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998; 28: 33-8.
48. Liermann Garcia RF, Evangelista GC, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22-7.
49. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20: 137-40.
50. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10: 1-7.
51. Neuberger JM, Gunson BK, Buckels JA, Elias E, McMaster P. Referral of patients with primary biliary cirrhosis for liver transplantation. Gut 1990; 31: 1069-72.
52. Rust C, Rau H, Gerbes AL, Pape GR, Haller M, Kramling H, et al. Liver transplantation in primary biliary cirrhosis: risk assessment and 11-year follow-up. Digestion 2000; 62: 38-43.
53. Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transpl Surg 1995; 1: 109-15.
54. Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995; 117: 146-55.
55. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver 2000; 20: 97-103.
56. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 1050-6.
57. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100: 1710-7.
58. Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992; 103: 1893-901.
59. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-5.
60. Boberg KM, Rocca G, Egeland T, Bergquist A, Broome U, Caballeria L, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002; 35: 652-7.
61. O'Grady JG. Treatment options for other hepatic malignancies. Liver Transpl 2000; 6(6 Suppl 2): S23-9.
62. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633-7.
63. Ghali P, Marotta PJ, Yoshida EM, Bain VG, Marleau D, Peltekian K, et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl 2005; 11: 1412-6.
64. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004; 24: 201-7.
65. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-7.
66. Brau N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S, et al. Prevalence of hepatitis C and co-infection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 2002; 97: 2071-8.
67. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-20.
68. Schvarcz R, Rudbeck G, Soderdahl G, Stahle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000; 69: 2194-5.
69. Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999; 68: 307-9.
70. Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003; 37: 1793-6.